What Should Be Chronic: The Animal, the Model, or Both?

Gustavo A Rubio; Sharon J Elliot; Marilyn K Glassberg

doi:10.5966/sctm.2015-0325

What Should Be Chronic: The Animal, the Model, or Both?

Stem Cells Transl Med. 2016 May;5(5):703. doi: 10.5966/sctm.2015-0325.

Authors

Gustavo A Rubio¹, Sharon J Elliot¹, Marilyn K Glassberg²

Affiliations

¹ Department of Surgery, University of Miami Leonard M. Miller School of Medicine, Miami, Florida, USA.
² Department of Surgery; Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Department of Medicine; and Division of Pediatric Pulmonology, Department of Pediatrics, University of Miami Leonard M. Miller School of Medicine, Miami, Florida, USA.

Abstract

The systematic review of mesenchymal stromal cell (MSC) therapy in pulmonary fibrosis by Srour and Thébaud published in a recent issue of Stem Cells Translational Medicine is critically reviewed; Rubio et al. suggest that bleomycin-induced lung injury in aged mice studied over time is a more clinically applicable model for human idiopathic pulmonary fibrosis.

Publication types

Letter
Comment

MeSH terms

Animals
Bleomycin / adverse effects*
Disease Models, Animal*
Humans
Mesenchymal Stem Cell Transplantation*
Mesenchymal Stem Cells / metabolism*
Pulmonary Fibrosis*

Substances

Bleomycin